<DOC>
	<DOCNO>NCT01998438</DOCNO>
	<brief_summary>Tranexamic acid , antifibrinolytic drug , wildly use cardiac surgery decrease perioperative bleeding allogenic transfusion . But optimum dose tranexamic acid still unknown . We use three different dos find optimum dose tranexamic acid cardiopulmonary bypass cardiac surgery .</brief_summary>
	<brief_title>Prospective Trial Tranexamic Acid Cardiac Surgery</brief_title>
	<detailed_description />
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Noncyanotic congenital heart disease patient require cardiac surgery cardiopulmonary bypass Rheumatic recessive valvular disease patient require valvular repair replacement cardiopulmonary bypass Coronary artery disease patient require coronary artery bypass graft cardiopulmonary bypass Nonprimary emergency cardiac surgery Disorder coagulation function surgery Anemia surgery Definite liver renal dysfunction History stroke Pregnancy lactation Disabled spirit law Fatal condition cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>tranexamic acid</keyword>
	<keyword>cardiac surgery</keyword>
	<keyword>cardiopulmonary bypass</keyword>
</DOC>